Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA-Reference-Cited by-同舟云学术

Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA

Published:2022-02-10 Issue:7 Volume:63 Page:1669-1677
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Wang Jiasheng¹^ORCID,Arroyo-Suarez Raul²,Dasari Srilatha²,Sekaran Kanithra²,Tse William³

Affiliation:

1. Department of Hematology and Oncology, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA

2. Department of Internal Medicine, MetroHealth Medical Center, Cleveland, OH, USA

3. Department of Hematology and Oncology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2038376

Reference22 articles.

1. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia

2. Early response to therapy and survival in multiple myeloma

3. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

4. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma

5. The impact of response kinetics for multiple myeloma in the era of novel agents

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial;eJHaem;2023-08-03

2. Modern Myeloma Therapy + Sustained Minimal Residual Disease–Negative = (Functional) Cure!;Journal of Clinical Oncology;2022-09-01